3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Lung Neoplasms
19
Ovarian Neoplasms
15
Carcinoma, Non-Small-Cell Lung
14
Fallopian Tube Neoplasms
13
Colorectal Neoplasms
11
Pancreatic Neoplasms
9
Carcinoma, Hepatocellular
8
Melanoma
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Urinary Bladder Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Mycosis Fungoides
5
Lymphoma, T-Cell, Cutaneous
5
Lymphoma, Large B-Cell, Diffuse
5
Prostatic Neoplasms
4
Neoplasms
4
Neoplasm Metastasis
4
Breast Neoplasms
4
Triple Negative Breast Neoplasms
3
Sezary Syndrome
3
Sarcoma
3
Rectal Neoplasms
3
Myelodysplastic Syndromes
3
Multiple Myeloma
3
Lymphoma, T-Cell
3
Leukemia, Myeloid, Acute
3
Glioblastoma
3
Colonic Neoplasms
3
Cholangiocarcinoma
3
Carcinoma, Renal Cell
3
Interventions
Paclitaxel
7
Doxorubicin
5
pembrolizumab
4
pazopanib
4
Gemcitabine
4
Bevacizumab
4
durvalumab
3
Radiotherapy
3
Propranolol
3
Docetaxel
3
regorafenib
2
cemiplimab
2
Surveys and Questionnaires
2
Sunitinib
2
Standard of Care
2
Nivolumab
2
Ifosfamide
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
tremelimumab
1
trebananib
1
trastuzumab duocarmazine
1
talimogene laherparepvec
1
talazoparib
1
spartalizumab
1
sintilimab
1
selinexor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Hemangiosarcoma
×
Disulfides
×
Clear all
NCT04668300
2026-04-15
DOSa
M.D. Anderson Cancer Center
Phase 2
Active not recruiting
75 enrolled